Topline results from a pooled clinical study show that Mainz Biomed’s portfolio of proprietary novel gene expression (mRNA) biomarkers can be used in a next generation version of the company’s colorectal cancer screening tool. The study included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, the company said.
COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.
